Watson has elected not to proceed with Uracyst for the United States market.

Stellar has commenced a review and analysis of the Watson Ur008 study. This review and analysis will, among other things, seek to determine what role, if any, factors such as cohort size and patient selection criteria may have had with the study's unexpected overall results. The company expects to base its go-forward strategy for Uracyst in the United States upon the findings of that review and analysis.

In June 2009, Watson received conditional approval for an Investigational Device Exemption to conduct clinical work with Uracyst from the FDA. This conditional approval led to the commencement of Watson Ur008, a double blind, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the U.S. Watson Ur008 was designed to strengthen the patient selection criteria for an anticipated larger pivotal study that, if successful, would support Watson's application with the FDA to obtain approval to market Uracyst in the United States.

Cancer and infectious disease vaccine addresses problems found with earlier immunotherapy approaches

Seattle-based TapImmune Inc. (OTCBB:TPIV) has engineered a simple way for the body to recognize tumor and infectious disease cells and provoke an aggressive immune response whereby the body's own killer T-Cells attack and eradicate harmful foreign bodies. This with respect to any form of cancer or disease via a technology that's entirely non-discriminate in helping the body eradicate dangerous cells of many kinds.

Underscoring the potential of TapImmune's approach is its exclusive licensing option agreement with the Mayo Clinic for a breast cancer antigen technology complementary to the company's TAP (AdhTAP) protocol. In a novel approach, TapImmune and the Mayo Clinic will co-develop a specialized vaccine for patients with very aggressive HER2/neu breast cancer. What's unique is that TapImmune's technology actually re-activates the body's own immune system, triggering mission-critical self-curative mechanisms that would otherwise not function properly.

"We chose to work with the Mayo Clinic because they have great clinical expertise in breast cancer, and we're focusing specifically on HER2/neu breast cancer because we found complementary technology with Mayo that will work with TAP and address the problems found with earlier approaches," explains Dr. Glynn Wilson, chairman and CEO of TapImmune. "Importantly, we're able to work with a leading expert on breast cancer vaccines, Dr. Keith Knutson of the Mayo Clinic, who will conduct the trials. Through these trials, we'll also address a huge clinical need for patients who express low to moderate levels of HER2/neu and are not candidates for treatment with Herceptin(R) (trastuzumab), an intravenously delivered monoclonal antibody."

TAP (transporters associated with antigen processing) plays a major role in the complex human

BURRILL CANADIAN BIOTECH NEWS
(ISSN: 1188-455X)
Founded: 1991
Published 46 times per year by the Burrill & Company., One Embarcadero Center, Suite 2700, San Francisco, CA 94111
Tel: (415) 591-5474 Fax: (415) 591-5401
www.canadianbiotechnews.com

SUBSCRIPTION
Annual: US$450

Annual bundle: US$775.00 (Includes Biotech 2010 report on the biotechnology and life sciences industries and a one-year subscription to the monthly Burrill Report)

Subscription Equiries:
pwinter@b-c.com

Subscription orders:
http://www.burrillandco.com/resources-34-0-0-46-Burrill_Canadian_Biotech_Weekly_News.html

EDITORIAL
Editor-in-Chief:
Peter Winter (pwinter@b-c.com)
Managing Editor:
Daniel Levine (dlevine@b-c.com)
Assistant Editor:
Marie Daghlian (mdaghlian@b-c.com)

ADVERTISING
Advertising Director:
Leslie Errington (lerrington@b-c.com)

immune system. When viruses and disease attack cells in the body, the normal response is for killer T-cells to find those invaders and destroy them. TAP is a transporter that helps trigger an immune response by providing a pathway for tumor antigens to be expressed on the surface of the cell. In most solid cancers TAP levels are greatly reduced, which prevents the antigen presentation required to stimulate T-cells into action.

In the treatment of cancer, TAP is analogous to turning on the light bulb on the surface of tumor cells, allowing immune cells to "see" them and inspire action accordingly. For infectious disease treatment, TAP turns the light bulb to a higher intensity to prompt more immune cells to act.

Indeed, TapImmune's technology is entirely unique in that it isn't dependent on genetics like other immunotherapies and doesn't directly target the tumor cells, but instead assists the body's own immune system to do what it was designed to do by turning the TAP back on and activating destroyer T-Cells into "kill" mode.

TAP and Breast Cancer

"For breast cancer, we are developing a unique multi-component vaccine that stimulates the Class 2 pathway (CD4 – helper cells) for a prolonged immune response and the Class 1 pathway (CD8 – cytotoxic T cells) to activate killer T-cells that will infiltrate and destroy tumor cells," Wilson explains. "The HER2/neu vaccines that had been tested in the past either do not stimulate sufficient cytotoxic T-cell response on the Class I pathway or they do not give a long-lasting effect. I realized that we have the capability here with the Mayo technology plus TAP of creating good responses on both sides of the immune system required for a good vaccine. It is a very innovative, creative and exciting approach."

TapImmune (formerly GeneMax) was formed in Vancouver , British Columbia , in the laboratories of immunologist Wilfred Jeffries.who with his colleagues produced data showing that administration of TAP to replace deficient levels in tumors or augment natural levels in viral disease had significant therapeutic effects in animal models. Four years ago, TapImmune principals acquired the technology and intellectual property outright from the university and set out to put together a board of directors and advisory board that understands the technology and its potential and to partner with credible collaborators.

"In discussions with Aeras Global TB Vaccine Foundation, we identified the potential of TAP for use in the joint development of their next-generation TB vaccine," said Denis Corin, TapImmune's president and CFO. "But you could also look at influenza, SARS, HIV H1N1 and many other societal pathogens. We're also working with Dr. Poland and the Mayo Clinic on a new small pox vaccine. But, small pox is the tip of the iceberg. There are a number of nasty viruses that are potential bioterrorism threats and governments around the world could stockpile our TAP vaccine and call on it in the event of a bioterrorist threat."

The Canadian Innovation Exchange (CIX)

The Canadian Innovation Exchange (CIX) - taking place December 7, 2010, in Toronto - is Canada's premier showcase for hot technologies and the people behind them, and a gathering of the who's who of the innovation economy. This one day forum offers a comprehensive understanding of the Canadian innovation landscape, as well as a structured opportunity to connect with the leading entrepreneurs, tech companies and investors in Canada.

CIX features facilitated one-on-one meetings, a slate of insightful sessions and speakers, and the Canada's Hottest Innovative Companies Showcase - a fast-paced, expertly-curated series of presentations by the CEOs of innovative companies in the Information and Communication Technologies, Digital Media and Clean Technology sectors.

The Canadian Innovation Exchange will:

• Yield a thorough understanding of the opportunities in the Canadian technology sector, including major players, hot companies and principal trends.

• Connect investors with dealflow and investing partners through facilitated one-on-one meetings.

• Facilitate the development of international networks by providing access to major players in the Canadian investment community, including the principal GPs and LPs, major tech companies and entrepreneurs.

For more details on CIX and to register, please visit www.canadianinnovationexchange.com.